CIMAB S.A.
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From CIMAB S.A.
Lilly Reacquires Aurora Kinase Inhibitor Via AurKa Buy For $110m
Many Aurora kinase inhibitors have entered development, but while none have had a successful end, Lilly believes the specificity of AurKa's AK-01 will make it a safer drug. The asset fits well into Lilly's oncology strategy, which includes both targeted therapies and immuno-oncology drugs.
Biocon Upbeat As It Tries To Undercut Roche On Herceptin
India’s Biocon has high expectations for its Herceptin biosimilar, but patient groups are vocal in their criticism of the drug’s price in comparison to Roche’s.
Deals Shaping The Medical Industry, January 2013
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment –In Vitro Diagnostics, Pharmaceuticals, and Medical Devices – and then categorized by type –Acquisition, Alliance, or Financing.
Serono Deals Its Way Into Oncology
It ought to be hard to convince an oncology-focused biotech to license its crown jewel to a firm without experience developing oncology drugs, but Serono SA was able to do just that-twice in the span of eight days-when it in-licensed Phase II and Phase III oncology programs, respectively, from Micromet AG and CancerVax Corp. in December.
Company Information
- Other Names / Subsidiaries
-
- InnoMab PTE Ltd.